A Toronto drug-repurposing company reached a $1 billion valuation through a round that was never announced — and the only hard public artifact is a share-registry filing.
Sourced, not announced. The deal was not announced; the details come from an unnamed person not authorised to discuss them, and the chief executive declined to comment. US$153 million is the round size — OpenAI’s own contribution is not disclosed and is described only as a majority, so nothing here says how much OpenAI itself put in. This article is not investment advice.Nothing about an unannounced private round is improper — the observation below is that the public record of this one is a share register rather than a statement, and that is not an accusation.
Not investment advice. All figures from The Globe and Mail reporting by Sean Silcoff, Sept. 28, 2026, sourced from an unnamed person not authorised to discuss the matter. CEO declined to comment. No press release exists.
Sean Silcoff reported in The Globe and Mail on September 28, 2026, that Biossil — a Toronto-based company that repurposes existing drug compounds — closed a $153 million all-equity round at a $1 billion valuation, led by the OpenAI Startup Fund, which provided the majority of the capital. The detail comes from a single unnamed person not authorised to discuss the financing. Biossil CEO Anthony Mouchantaf declined to comment. There is no press release, no fund statement, and no public acknowledgment from any named party.
Named co-investors include Founders Fund, Quiet Capital, Modern Capital, Golden Ventures, Panache Ventures, Duke University’s endowment fund, and the Abu Dhabi Investment Council. A small portion of the round was paid to early employees rather than going to the company directly. The stated use of proceeds is expanding clinical development capacity and selectively acquiring additional drug candidates.
OpenAI’s actual dollar contribution is not a known number. “Majority” is the only quantifier the reporting provides. Nothing published establishes what OpenAI wrote into this round or any prior one — and that limit is not a detail. It is the central structural fact of this story.
The key insight: The only hard public artifact produced by this $153 million financing is a Corporations Canada share-registry filing — 5.37 million preferred shares at US$28.69 each, recorded in August. That filing gives a price and a count. It does not name buyers. The document that exists is shaped by what corporate law in Canada happens to require, not by what an informed observer would want to know.
The rungs are verified. What is not on the chart is how much of any of them was OpenAI’s money.
The Structural Read
Private markets have always had an announcement problem. But something is shifting in how the largest AI-adjacent rounds get disclosed — or don’t. The Biossil deal was not kept quiet through evasion. It was kept quiet simply because no party with authority chose to speak. The result is that the public record of a $153 million financing round consists of a government registry entry and a single sourced newspaper story.
This is the architecture of disclosure when there is no announcement: the filing surface takes over. It is incomplete, it lags the event, and it answers the wrong questions. The Corporations Canada entry tells you that shares were issued and at what price. It does not tell you who holds them. The one number observers most want — how much each party committed — is precisely the number the filing omits.
The ladder behind this round is short and, unusually for a story of this kind, fully itemised in the reporting. A US$3.7 million seed in 2023, led by Janet Bannister’s Staircase Ventures. US$22 million in 2024, led by Founders Fund. About US$43 million roughly a year ago, co-led by the OpenAI Startup Fund and Founders Fund. And now US$153 million at a US$1 billion valuation, led by the OpenAI Startup Fund — which is where the public trail stops and the share register begins.
The share-price data embedded in the filing does offer one internally consistent signal. At US$28.69 per share — approximately triple the per-share price from the prior round — and with a round roughly 3.5 times the size of its predecessor, the two multiples rhyme. That is an observation about two ratios and nothing further — it supports no conclusion about what proportion of the company changed hands. No ownership percentage, no dilution figure, and no prior share price is given anywhere in this reporting, and none is calculated here.
Structural Observation
“When deals stop being announced, the disclosure surface moves to whatever registry the jurisdiction happens to require — and that surface is incomplete, lagging, and shaped by corporate law rather than by what an observer would want to know.”
On what Biossil actually does: the company has bought or licensed 12 drug molecules. In July 2026 it paid Summit Therapeutics $500,000 upfront for a precision antibiotic targeting Clostridioides difficile, with additional payments contingent on regulatory and commercial milestones. No milestone amounts are established in the reporting, no clinical results or trial phases are given, and no revenue or headcount figures appear — a limit of what has been published, not evidence that none exist.
The OpenAI Startup Fund has now appeared on the last two rungs of Biossil’s financing ladder: co-leading a round of roughly $43 million about a year ago, and leading this $153 million round. This publication noted earlier today that the OpenAI Startup Fund also holds two AI-biosecurity seed positions with a combined round size of approximately $45 million. The honest comparison available is round-to-round: $153 million against approximately $45 million. It is not a comparison of OpenAI’s own money, because its cheque sizes are undisclosed across all of these deals. Nothing here asserts OpenAI spent more on one investment than another.
Three Implications
IMPLICATION 1 — THE REGISTRY IS THE NEW PRESS RELEASE
As consequential AI-adjacent rounds go unannounced, corporate registries become the de facto disclosure channel for investors, journalists, and researchers. The catch: registries answer legal questions, not commercial ones. Price and share count appear; buyer identity does not. Anyone building a portfolio-tracking system around press releases is already working with an incomplete map.
IMPLICATION 2 — DRUG REPURPOSING AS AN AI DEPLOYMENT SURFACE
Biossil’s model — acquire or license existing molecules, apply computational analysis to find new clinical applications — is one of the cleaner structural fits for AI-accelerated biology. The assets already exist; the question is pattern-matching across mechanism, indication, and regulatory pathway. A $1 billion valuation on a 12-molecule portfolio suggests sophisticated investors believe the computational layer can do that faster than traditional drug discovery timelines allow.
IMPLICATION 3 — THE UNNAMED-SOURCE ROUND IS A CATEGORY NOW
This is not the first major AI-adjacent financing to surface through a single sourced report rather than a company announcement. When the parties most motivated to tell the story — the company, the lead investor, the syndicate — all decline, the result is a valuation that enters the public record with a credibility discount baked in. That discount does not mean the round didn’t happen. It means the standard tools for verifying it don’t exist.
Business Engineer Framework
The Map of AI — Where Biossil Sits in the Stack
Biossil is not building a foundation model or an inference stack. It is a Harnesser in the Map of AI framework: a company whose competitive position depends on acquiring proprietary assets — in this case, drug molecules and clinical data — and applying AI capabilities it largely does not build itself. The structural question the Map of AI surfaces is which layer owns the durable value: the model, the data, or the domain. In drug repurposing, the domain assets (molecules, indications, regulatory pathways) are the hard-to-replicate layer. Explore the full framework.
A $153 million round at a $1 billion valuation, led by the most closely watched investor in the industry, surfaced not through an announcement but through a registry filing and a single unnamed source — and the one number that matters most, OpenAI’s actual cheque, remains undisclosed. That is not a footnote to the Biossil story; it is the story. Private capital at scale is developing a new norm in which the press release is optional, the registry is the artifact, and the public record is shaped by whatever corporate law happens to require rather than by what would actually inform an observer. Track the filings, not the announcements. This is not investment advice.
Source: The Globe and Mail — Sean Silcoff, September 28, 2026. All figures and deal details sourced from that reporting, which draws on an unnamed person not authorised to discuss the matter. CEO Anthony Mouchantaf declined to comment. No press release or official confirmation exists as of publication. Nothing in this article constitutes investment advice.
Sourced, not announced. The round was not announced; the details come from an unnamed person not authorised to discuss them, and chief executive Anthony Mouchantaf declined to comment. US$153 million is the total round size. OpenAI’s own contribution is not disclosed anywhere and is described only as a majority of the round, so nothing above states how much OpenAI itself invested. Where this round is set against the OpenAI Startup Fund’s AI-biosecurity positions, the comparison is between round sizes and not between OpenAI’s cheques, which are undisclosed in those rounds; nothing above says OpenAI spent more on one than the other, and nothing above frames them as competing priorities. Last year’s share price is not given and is not derived above; no ownership percentage or dilution figure is calculated. The third round is dated in the reporting only as about a year ago. Material in the same source article concerning another company’s laboratory work is separate context and is not part of this financing. OpenAI’s contribution to any round, Biossil’s revenue, headcount, burn and runway, which molecules it holds, any clinical result, trial phase or approval, and the Summit milestone amounts are not established and do not appear — a limit of this reporting rather than evidence that none exist. Nothing above is investment advice, and nothing above predicts Biossil, OpenAI, drug repurposing or any valuation.
Gennaro Cuofano is a CRO and tech executive who has worked in AI since late 2015, starting with bringing NLP, natural-language generation, voice and chatbot products to the marketing industry. His background is in law and finance: he holds a Master's degree in Law and an International MBA with an emphasis on corporate finance (LUISS Business School and the University of San Diego, 2012), and worked as a financial analyst at a real-estate investment firm in San Diego and as an assistant controller. His work focuses on business model strategy, business engineering and, more broadly, structural analysis: how companies make money, read from their own filings. He created FourWeekMBA and leads research there and at The Business Engineer, his newsletter on AI and business strategy, with over 95,000 subscribers and more than 1,000 published analyses. His writing has also appeared on Entrepreneur (for example, How to Digitize a Family Business in Europe) and HackerNoon. Find him on LinkedIn and Substack. See how we source.
